Practical Bayesian guidelines for phase IIB clinical trials.

A Phase IIB clinical trial typically is a single-arm study aimed at deciding whether a new treatment E is sufficiently promising, relative to a standard therapy, S, to include in a large-scale randomized trial. Thus, Phase IIB trials are inherently comparative even though a standard therapy arm usually is not included. Uncertainty regarding the response rate theta s of S is rarely made explicit, either in planning the trial or interpreting its results. We propose practical Bayesian guidelines for deciding whether E is promising relative to S in settings where patient response is binary and the data are monitored continuously. The design requires specification of an informative prior for theta s, a targeted improvement for E, and bounds on the allowed sample size. No explicit specification of a loss function is required. Sampling continues until E is shown to be either promising or not promising relative to S with high posterior probability, or the maximum sample size is reached. The design provides decision boundaries, a probability distribution for the sample size at termination, and operating characteristics under fixed response probabilities with E.

[1]  Choi Sc,et al.  Monitoring clinical trials based on predictive probability of significance. , 1989 .

[2]  D. Berry,et al.  Interim analyses in clinical trials: classical vs. Bayesian approaches. , 1985, Statistics in medicine.

[3]  P. Thall,et al.  Incorporating historical control data in planning phase II clinical trials. , 1990, Statistics in medicine.

[4]  D. Lindley,et al.  Inference for a Bernoulli Process (a Bayesian View) , 1976 .

[5]  J. Herson,et al.  Predictive probability early termination plans for phase II clinical trials. , 1979, Biometrics.

[6]  Donald A. Berry,et al.  Interim analysis in clinical trials; the role of the likelihood principle , 1987 .

[7]  R. Varga,et al.  Proof of Theorem 4 , 1983 .

[8]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[9]  Sylvester Rj,et al.  Design of phase II clinical trials in cancer using decision theory. , 1980 .

[10]  Richard Sylvester A bayesian approach to the design of phase II clinical trials. , 1988 .

[11]  P. Meier,et al.  Statistics and medical experimentation. , 1975, Biometrics.

[12]  J. Cornfield A BAYESIAN TEST OF SOME CLASSICAL HYPOTHESES- WITH APPLICATIONS TO SEQUENTIAL CLINICAL TRIALS , 1966 .

[13]  K C Cain,et al.  Charts for the early stopping of pilot studies. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Melvin R. Novick,et al.  A Bayesian Approach to the Analysis of Data from Clinical Trials , 1965 .

[15]  Chih-Hsiang Ho Some Frequentist Properties of a Bayesian Method in Clinical Trials , 1991 .

[16]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[17]  Irene A. Stegun,et al.  Handbook of Mathematical Functions. , 1966 .

[18]  D. Spiegelhalter,et al.  A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. , 1986, Statistics in medicine.

[19]  J. Cornfield Sequential Trials, Sequential Analysis and the Likelihood Principle , 1966 .